Active Trials at UCLA Health Alpha Clinic
| Trial Sponsor |
Disease Indication |
Clinical Trial Name |
ClinicalTrials.gov Identifier |
IRB # |
Phase |
STATUS CT.GOV |
| CIRM |
Blood Disorders |
Clinical Research Study of Autologous Bone Marrow Transplantation for Sickle Cell Disease (SCD) Using Bone Marrow CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral Vector |
NCT02247843 |
13-000288 |
Phase 1/2 |
Recruiting |
| Merck; CIRM |
Cancer |
A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab Foradvanced NSCLC |
NCT03546361 |
17-000174 |
Phase 1 |
Recruiting |
| CIRM; NEI |
Vision Loss |
Stem Cell-Based Therapy for Limbal Stem Cell Deficiency |
NCT03957954 |
19-001056 |
Phase 1 |
Recruiting |
| Astellas Pharma, Inc. |
Vision Loss |
A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 forGeographic Atrophy Secondary to Age-related Macular Degeneration |
NCT03178149 |
17-000835 |
Phase 1 |
Recruiting |
| CIRM, UCLA |
Immune Disease |
Efficacy And Safety Of Cryopreserved Autologous Mobilized Peripheral Blood CD34+ Hematopoietic Stem And Progenitor Cells Transduced Ex Vivo With The EFS-ADA Lentiviral Vector In Patients With Severe Combined Immune Deficiency Due To Adenosine Deaminase Deficiency |
NCT05432310 |
21-001814 |
Phase 1/2 |
Recruiting |
| Neurona Therapeutics Inc. |
Neurological Disorders |
A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE) |
NCT05135091 |
21-001132 |
Phase 1/2 |
Recruiting |
